Qiagen : Q2 numbers due 27 July at 22:05 CET – Expecting a positive surprise
>Q2 forecast above consensus - We estimate Q2 sales of $ 510m, a c. 10% y-o-y decline (-5% y-o-y ex FX). We estimate non-Covid-related product sales of $ 413m, only +6% y-o-y ex FX. However, last year’s Q2 benefitted from a special positive item of $ 20m in the Genomics product portfolio for technology license sales. Hence, we estimate a 12% y-o-y underlying sales growth ex FX for this franchise. Covid-related product sales we estimate at $ 97m ($ 50m quarterly run ra...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.